Sectors
GERN
Geron Corporation
1.42
786 x 1.41
544 x 1.42
bid
ask
-
0.02
1.74%
1653 @ 04:00 PM
1.44 +0.02 (1.77%)
| Ytd | 7.20% | |
| 1y | 10.55% |
1.40
day range
1.45
1.04
52 week range
2.01
| Open | 1.44 | Prev Close | 1.44 | Low | 1.40 | High | 1.45 | Mkt Cap | 907.75M |
| Vol | 4.93M | Avg Vol | 13.04M | EPS | -0.09 | P/E | -15.72 | Forward P/E | 24.00 |
| Beta | 0.60 | Short Ratio | 6.52 | Inst. Own | 79.65% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 1.31 | 200-d Avg | 1.40 | 1yr Est | 3.40 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-05 | 2026-06 | -0.01 | N/A | N/A | N/A |
| 2026-05-06 | 2026-03 | -0.03 | -0.01 | 0.02 | 66.67% |
| 2026-02-25 | 2025-12 | -0.03 | -0.03 | N/A | N/A |
| 2025-11-05 | 2025-09 | -0.04 | -0.03 | 0.01 | 18.19% |
| 2025-08-06 | 2025-06 | -0.03 | -0.02 | 0.01 | 33.33% |
| 2025-05-07 | 2025-03 | -0.04 | -0.03 | 0.01 | 25.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2025-11-05 | Needham | Upgrade | Buy | Buy |
| 2025-05-08 | Scotiabank | Downgrade | Sector Outperform | Sector Perform |
| 2025-03-12 | Needham | Upgrade | Buy | Buy |
| 2025-03-12 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
| 2025-02-27 | Scotiabank | Upgrade | Sector Outperform | Sector Outperform |
| 2025-02-27 | Stifel | Upgrade | Buy | Buy |
Profile
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-05-08 | LAWLIS VIRGIL BRYAN JR. | Director | 13.30K | Purchase |
| 2026-02-17 | ROBERTSON MICHELLE | Chief Financial Officer | 17.65K | Sale |
| 2025-02-26 | SAMUELS SCOTT ALAN | Officer | 26.68K | Purchase |
| 2025-02-26 | SCARLETT JOHN A | Chief Executive Officer | 137.50K | Purchase |
| 2026-06-29 | SPIEGEL ROBERT J | Director | 205.81K | Stock Award(Grant) |
| 2025-02-26 | ZIEGLER JAMES | Officer | 100.00K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | RA Capital Management, L.P. | 63.77M | 99.48M | 9.94% |
| 2026-03-30 | Blackrock Inc. | 47.32M | 73.82M | 7.38% |
| 2026-03-30 | Soleus Capital Management, L.P. | 41.51M | 64.75M | 6.47% |
| 2026-03-30 | Deep Track Capital, Lp | 31.72M | 49.48M | 4.94% |
| 2026-03-30 | State Street Corporation | 30.50M | 47.58M | 4.75% |
| 2026-03-30 | Vanguard Capital Management LLC | 26.67M | 41.60M | 4.16% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 20.05M | 31.29M | 3.13% |
| 2026-05-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 18.39M | 28.69M | 2.87% |
| 2026-05-30 | iShares Trust-iShares Russell 2000 ETF | 12.93M | 20.17M | 2.02% |
| 2026-04-29 | Vanguard Explorer Fund | 10.17M | 15.87M | 1.59% |
| 2026-04-29 | Legg Mason Partners Investment Trust-ClearBridge Small Cap Growth Fund | 6.32M | 9.85M | 0.98% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 5.95M | 9.29M | 0.93% |
Split
| Split | Date |
|---|---|
| 1058 : 1000 | 2014-07-22 |